Huntington's disease (HD) is caused by an expanded polyglutamine repeat in huntingtin protein that disrupts synaptic function in specific neuronal populations and results in characteristic motor, cognitive and affective deficits. Histopathological hallmarks observed in both HD patients and genetic mouse models include the reduced expression of synaptic proteins, reduced medium spiny neuron (MSN) dendritic spine density and decreased frequency of spontaneous excitatory post-synaptic currents (sEPSCs). Early down-regulation of cannabinoid CB 1 receptor expression on MSN (CB 1 (MSN) ) is thought to participate in HD pathogenesis. Here we present a cell-specific genetic rescue of CB 1(MSN) in R6/2 mice and report that treatment prevents the reduction of excitatory synaptic markers in the striatum (synaptophysin, vGLUT1 and vGLUT2), of dendritic spine density on MSNs and of MSN sEPSCs, but does not prevent motor impairment. We conclude that loss of excitatory striatal synapses in HD mice is controlled by CB 1(MSN) and can be uncoupled from the motor phenotype.
Introduction
The early down-regulation of CB 1 (MSN) was first observed in postmortem tissue of HD patients and occurs in most mouse models of HD, including R6/2, R6/1, YAC128 and HdhQ150 mice (Dowie et al., 2009; Glass et al., 2000; Pouladi et al., 2012; Woodman et al., 2007) . It was recently reported that mutant huntingtin acts at the Cnr1 promoter and inhibits CB 1 expression in neurons (Blázquez et al., 2010) . Downregulation of CB 1 (MSN) -the neuronal population expressing the highest amount of CB 1 receptors (Herkenham et al., 1990 ) -precedes the loss of other synaptic proteins, including dopamine D2 and D1 receptors and striatal synaptophysin (Glass et al., 2000) . Furthermore, it is known that functional CB 1 receptor signaling allows neurons to better resist various insults and pathological events by, for example, reducing excitotoxicity and regulating growth factor expression (Katona and Freund, 2008) . Together, this evidence led to the hypothesis that CB 1(MSN) dysfunction controls downstream pathological events occurring in HD patients and mouse models (Maccarrone et al., 2007) . For example, the genetic deletion of CB 1 receptors in HD mice both accelerates the motor phenotype and aggravates HD pathogenesis measured in the striatum, suggesting that CB 1 signaling might participate through an unknown mechanism in the development of HD (Blázquez et al., 2010; Mievis et al., 2011) . In line with this result, environmental enrichment both improves the phenotype of HD mice and increases CB 1 receptor expression in MSNs, without rescuing the expression of other proteins (D1, D2, and GABA A receptors) (Glass et al., 2004) . Nevertheless, other groups have suggested that CB 1 loss in HD may in fact be a compensatory event that corrects impaired D2 receptor signaling (Eidelberg and Surmeier, 2011) .
Several attempts to increase CB 1 signaling by pharmacological treatment in HD mice have resulted in divergent conclusions. One study treated R6/1 mice with a full CB 1 agonist (HU210), a partial CB 1 agonist (THC), or an inhibitor (URB597) of fatty acid amide hydrolase, an enzyme known to inactivate the prototypical endocannabinoid anandamide, and found that none of these treatments improved the motor phenotype of R6/1 mice (Dowie et al., 2010) . Conversely, another study treated R6/2 mice with a lower concentration of THC (2 mg/kg, compared with 10 mg/kg) and found improvement in several motor and neuropathological measures (Blázquez et al., 2010 
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